研究疾病:
|
慢性紧张性头痛
|
研究疾病代码:
|
|
Target disease:
|
Chronic tension headache
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
探索性研究/预试验
Pilot clinical trial
|
研究目的:
|
明确柴芎止痛汤治疗慢性紧张性头痛患者的临床疗效;观察慢性紧张性头痛与白介素-6(IL-6)、C反应蛋白等炎症因子的相关性及治疗前后改变情况。
|
Objectives of Study:
|
To observe the relationship between chronic tension headache and inflammatory factors such as interleukin-6(IL-6) , c-reactive protein (CRP), and the changes before and after treatment.
|
药物成份或治疗方案详述:
|
(1)试验组:①予以柴芎止痛汤,具体药味如下,柴胡15g、延胡索30g、郁金15g、白芍20g、川芎20g、赤芍15g、白芷20g、防风15g、首乌藤20g、合欢皮20g。②中药详情:柴芎止痛汤使用中药免煎剂,由三九医药生产颗粒剂,安慰剂也由该厂提供。③每日3次,每次1包,加水150ml冲服,疗程2周。
(2)对照组:予安慰剂,口味、剂量、服药方法、疗程无明显差别。
|
Description for medicine or protocol of treatment in detail:
|
In the experimental group:
1. Chaixiong Zhitong decoction was given. The specific taste was as follows: Chaihu 15g, yanhusuo 30g, Yujin 15g, Baishao 20g, Chuanxiong 20g, Chishao 15g, Baizhi 20g, Fangfeng 15g, shouwuteng 20g, hehuanpi 20g.
2. Details of traditional Chinese medicine: chaixiong Zhitong decoction uses traditional Chinese medicine free decoction, granules are produced by Sanjiu medicine, and placebo is also provided by the factory.
3. 3 times a day, 1 bag each time, water 150ml, treatment for 2 weeks.
The control group was given placebo, and there was no significant difference in taste, dosage, medication method and course of treatment.
|
纳入标准:
|
①符合紧张性头痛西医诊断标准及中医气滞血瘀证标准;
②性别不限, 年龄18-65岁者;
③有头痛发作史, 本次疼痛时间不超过72h者;
④受教育年限≥6年,能坚持记录6周头痛日记者;
⑤知情同意,志愿受试。
|
Inclusion criteria
|
1. Subjects who met the diagnostic criteria of Western medicine and qi stagnation and blood stasis syndrome of traditional Chinese medicine;
2. Subjects of any gender, aged 18-65 years old;
3. Subjects with history of headache, whose pain time was less than 72 hours;
4. Subjects who have been educated for more than 6 years and can keep headache diary for 6 weeks;
5. Subjects with informed consent, volunteers.
|
排除标准:
|
①白介素-1、C反应蛋白异常或正在接受抗炎治疗;
②正在使用抗血小板药、抗凝药、他汀类药或激素等药物;
③合并严重的其他器质性病变包括恶性肿瘤、结核、骨折、骨髓炎等;
④合并有心脑血管、肝、肾和造血系统等严重原发性疾病;
⑤有严重精神障碍及智能障碍不能配合者;
⑥有需要住院的情况;
⑦有出血倾向、过敏体质者及皮肤病患者;
⑧孕妇及哺乳期妇女、近半年有生育要求者;
⑨正在参加其他临床试验者。
|
Exclusion criteria:
|
1. Patients with abnormal IL-1 and CRP or undergoing anti-inflammatory treatment;
2. Patients who are using antiplatelet drugs, anticoagulants, statins or hormones;
3. Patients with severe organic diseases, including malignant tumor, tuberculosis, fracture, osteomyelitis, etc;
4. Patients with serious primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system;
5. Patients with severe mental disorder and mental retardation who can't cooperate;
6. Patients who need to be hospitalized;
7. Patients with bleeding tendency, allergic constitution and skin diseases;
8. Pregnant women and lactating women, and those who have fertility requirements in the past six months;
9. Subjects who are participating in other clinical trials.
|
研究实施时间:
Study execute time:
|
从From
2021-03-01
至To
2022-04-01
|
征募观察对象时间:
Recruiting time:
|
从From
2021-04-01
至To
2022-03-01
|